Drug Evaluation, Preclinical
"Drug Evaluation, Preclinical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
Descriptor ID |
D004353
|
MeSH Number(s) |
E05.295.750 E05.337.550
|
Concept/Terms |
Drug Evaluation, Preclinical- Drug Evaluation, Preclinical
- Drug Evaluations, Preclinical
- Drug Screening
- Drug Screenings
- Screening, Drug
- Screenings, Drug
- Evaluation Studies, Drug, Pre-Clinical
- Preclinical Drug Evaluations
- Evaluation, Preclinical Drug
- Evaluations, Preclinical Drug
- Preclinical Drug Evaluation
- Drug Evaluation Studies, Preclinical
- Evaluation Studies, Drug, Preclinical
|
Below are MeSH descriptors whose meaning is more general than "Drug Evaluation, Preclinical".
Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation, Preclinical".
This graph shows the total number of publications written about "Drug Evaluation, Preclinical" by people in this website by year, and whether "Drug Evaluation, Preclinical" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1980 | 0 | 1 | 1 | 1983 | 0 | 1 | 1 | 1986 | 0 | 4 | 4 | 1988 | 1 | 0 | 1 | 1989 | 0 | 2 | 2 | 1990 | 0 | 1 | 1 | 1991 | 0 | 1 | 1 | 1993 | 0 | 1 | 1 | 1995 | 0 | 2 | 2 | 1996 | 0 | 1 | 1 | 1999 | 0 | 1 | 1 | 2002 | 0 | 1 | 1 | 2003 | 0 | 2 | 2 | 2004 | 2 | 1 | 3 | 2006 | 1 | 3 | 4 | 2007 | 1 | 2 | 3 | 2008 | 0 | 5 | 5 | 2009 | 0 | 2 | 2 | 2010 | 0 | 4 | 4 | 2011 | 2 | 2 | 4 | 2012 | 0 | 4 | 4 | 2013 | 2 | 4 | 6 | 2014 | 0 | 5 | 5 | 2015 | 0 | 6 | 6 | 2016 | 1 | 0 | 1 | 2017 | 0 | 4 | 4 | 2018 | 1 | 1 | 2 | 2019 | 1 | 4 | 5 | 2020 | 1 | 4 | 5 | 2021 | 0 | 5 | 5 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.
-
Perea-Gil I, Seeger T, Bruyneel AAN, Termglinchan V, Monte E, Lim EW, Vadgama N, Furihata T, Gavidia AA, Arthur Ataam J, Bharucha N, Martinez-Amador N, Ameen M, Nair P, Serrano R, Kaur B, Feyen DAM, Diecke S, Snyder MP, Metallo CM, Mercola M, Karakikes I. Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy. Eur Heart J. 2022 09 21; 43(36):3477-3489.
-
Cai X, Chen M, Prominski A, Lin Y, Ankenbruck N, Rosenberg J, Nguyen M, Shi J, Tomatsidou A, Randall G, Missiakas D, Fung J, Chang EB, Penaloza-MacMaster P, Tian B, Huang J. A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2. Adv Sci (Weinh). 2022 01; 9(2):e2103240.
-
Smiley SB, Yun Y, Ayyagari P, Shannon HE, Pollok KE, Vannier MW, Das SK, Veronesi MC. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. Pharm Res. 2021 Jun; 38(6):1067-1079.
-
Khan P, Siddiqui JA, Lakshmanan I, Ganti AK, Salgia R, Jain M, Batra SK, Nasser MW. RNA-based therapies: A cog in the wheel of lung cancer defense. Mol Cancer. 2021 03 19; 20(1):54.
-
Marinec PS, Landgraf KE, Uppalapati M, Chen G, Xie D, Jiang Q, Zhao Y, Petriello A, Deshayes K, Kent SBH, Ault-Riche D, Sidhu SS. A Non-immunogenic Bivalent d-Protein Potently Inhibits Retinal Vascularization and Tumor Growth. ACS Chem Biol. 2021 03 19; 16(3):548-556.
-
Gupta Y, Maciorowski D, Zak SE, Jones KA, Kathayat RS, Azizi SA, Mathur R, Pearce CM, Ilc DJ, Husein H, Herbert AS, Bharti A, Rathi B, Durvasula R, Becker DP, Dickinson BC, Dye JM, Kempaiah P. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays. Methods. 2021 11; 195:57-71.
-
Zhou DC, Zheng G, Jia LY, He X, Zhang CF, Wang CZ, Yuan CS. Comprehensive evaluation on anti-inflammatory and anti-angiogenic activities in vitro of fourteen flavonoids from Daphne Genkwa based on the combination of efficacy coefficient method and principal component analysis. J Ethnopharmacol. 2021 Mar 25; 268:113683.
-
Prescott K, Jacobs M, Stock W, Wynne J. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr Hematol Malig Rep. 2020 12; 15(6):424-435.
-
Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, Tang X, Yaron TM, Zhang T, Uhl S, Bram Y, Richardson C, Zhu J, Zhao Z, Redmond D, Houghton S, Nguyen DT, Xu D, Wang X, Jessurun J, Borczuk A, Huang Y, Johnson JL, Liu Y, Xiang J, Wang H, Cantley LC, tenOever BR, Ho DD, Pan FC, Evans T, Chen HJ, Schwartz RE, Chen S. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021 01; 589(7841):270-275.
-
Pimentel MB, Borges FTP, Teymour F, Zaborina OY, Alverdy JC, Fang K, Hong SH, Staneviciute A, He YJ, Papavasiliou G. An in vitro tissue model for screening sustained release of phosphate-based therapeutic attenuation of pathogen-induced proteolytic matrix degradation. J Mater Chem B. 2020 03 25; 8(12):2454-2465.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|